Saturday, 21 July, 2018

Juno Therapeutics Inc. (NASDAQ:JUNO) has Current Market Capitalizaion of $2.47 Billion

Melissa Porter | 04 March, 2017, 00:58

Juno brings together innovative technologies from some of the world's leading research institutions, including the Fred Hutchinson Cancer Research Center, Memorial Sloan Kettering Cancer Center, Seattle Children's Research Institute (SCRI), the University of California, San Francisco, and The National Cancer Institute. Zacks Investment Research cut Juno Therapeutics from a "hold" rating to a "sell" rating in a research note on Tuesday, January 10th. Leerink Swann reissued an "outperform" rating and set a $34.00 target price (down from $45.00) on shares of Juno Therapeutics in a report on Monday, November 28th. The share price is now 1.24 percent versus its SMA20, 9.23 percent versus its SMA50, and -21.54 percent versus its SMA200.

Currently, the stock carries a price to earnings ratio of 0, a price to book ratio of 7.94, and a price to sales ratio of 24.55. Juno Therapeutics has a 12-month low of $17.52 and a 12-month high of $49.72. News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Juno Therapeutics, Inc. with's FREE daily email newsletter. The difference between the expected and actual EPS was $-0.04/share, which represents an Earnings surprise of -6.6%. Back on Dec 06, 2016, a downgrade report came from equity analysts at Raymond James who in their research findings assigned Mkt Perform rating on the stock. The Market Capitalization of the company stands at 2.47 Billion. For the twelve months ended December 31, 2016, the net loss was $280.0 million, or $1.03 per share, compared to a net loss of $156.9 million, or $0.60 per share, for the same period in 2015.

The stock's 50 day moving average is 21.21 and its 200 day moving average is 25.08. These analysts have also projected a Low Estimate of $-0.91/share and a High Estimate of $-0.74/share. The analyst projections are -$0.71 in EPS on $10.56 million in revenues. The volume of 5.76 Million shares climbed up over an trading activity of 1.76 Million shares.

The company's Phase II program was twice halted a year ago by the US Food and Drug Administration and remained on hold due to severe neurotoxicity that led to five patient deaths from cerebral edema. Metropolitan Life Insurance Co. OMERS ADMINISTRATION Corp now owns 102,700 shares of the biopharmaceutical company's stock valued at $3,082,000 after buying an additional 54,200 shares during the last quarter. First Washington CORP raised its stake in Juno Therapeutics by 64.5% in the third quarter. Commerzbank Aktiengesellschaft FI acquired a new position in shares of Juno Therapeutics during the fourth quarter worth $192,000. Institutional investors own 61.80% of the company's stock.

Juno Therapeutics, Inc. (Juno) is a biopharmaceutical company focused on re-engaging the body's immune system to revolutionize the treatment of cancer.

Bishop said characteristics of the immunotherapy treatment the patients received, including the number and type of T cells used in the treatment, was one of three reasons that the patients developed toxicity that eventually killed them.